Bicara Net Income Per Share from 2010 to 2026
| BCAX Stock | | | 20.01 -0.05 -0.25% |
Bicara Therapeutics' Net Loss is decreasing over recent years with slightly volatile volatility. It is projected to decline toward -1.51. From 2010 to 2026, Bicara Therapeutics Net Loss regression analysis produced a arithmetic mean of
-0.87 . with significance of
0.001 .
View All Fundamentals Net Loss | First Reported 2010-12-31 | Previous Quarter -1.44 | Current Value -1.51 | Quarterly Volatility 0.26770816 |
Macro event markers
Credit Downgrade | Yuan Drop | Covid | Interest Hikes |
Review
Bicara Therapeutics Correlation against competitors for Bicara Therapeutics. This adds peer-relative context.
Analyzing Bicara Therapeutics's Net Income Per Share over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income Per Share has evolved provides context for assessing Bicara Therapeutics's current valuation and future prospects.
Latest Bicara Therapeutics' Net Income Per Share Growth Pattern
Below is the plot of the Net Income Per Share of Bicara Therapeutics Common over the last few years. It is Bicara Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Bicara Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Net Income Per Share | 10 Years Trend | | |
Bicara Net Income Per Share Regression Statistics
| Arithmetic Mean | -0.87 |
| Coefficient Of Variation | -30.94 |
| Mean Deviation | 0.21 |
| Median | -0.73 |
| Standard Deviation | 0.27 |
| Sample Variance | 0.07 |
| Range | 0.7789 |
| R-Value | -0.72 |
| Mean Square Error | 0.04 |
| R-Squared | 0.52 |
| Significance | 0.001 |
| Slope | -0.04 |
| Total Sum of Squares | 1.15 |
Bicara Net Income Per Share History
| 2026 | -1.51 | |
| 2025 | -1.44 | |
| 2024 | -1.25 | |
| 2023 | -1.0 | |
About Bicara Therapeutics Inc. Common Stock
Bicara Therapeutics is an entity of United States traded as a Stock on the NASDAQ Exchange exchange. The stock overview for Bicara Therapeutics summarizes business drivers, financial profile, and market behavior. The company is positioned within Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care. Current metrics include P/B of 3.23. Bicara Therapeutics has market cap of 1.3 B, ROE of -26.64%.
Methodology
Unless otherwise specified, financial data for Bicara Therapeutics Common is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Bicara (USA Stocks:BCAX) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: We use public filings and market reference sources with disclosures published by U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Patent & Trademark Office (USPTO) as reference inputs. Data may be normalized and can be delayed. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
Bicara Therapeutics Common is covered by 13 analysts. 6 analysts have submitted revenue and/or earnings estimates that may be incorporated into Macroaxis consensus inputs where available. Representative analyst firms may include Bernstein Research, Deutsche Bank, Morgan Stanley, BMO Capital Markets, Guggenheim Securities, Jefferies, among others. Updates may occur throughout the day.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
More Resources for Bicara Stock Analysis
A structured review of Bicara Therapeutics often starts with core
financial statements and trend context. Key ratios help frame profitability, efficiency, and growth context for Bicara Therapeutics Common Stock.
Outlined below are key reports that provide context for Bicara Therapeutics Common Stock: Review
Bicara Therapeutics Correlation against competitors for Bicara Therapeutics. This adds peer-relative context.
Analysis related to Bicara Therapeutics should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the
Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Earnings Share 5.38 | Return On Assets | Return On Equity |
The market value of Bicara Therapeutics is measured differently than book value, which reflects Bicara accounting equity. Bicara Therapeutics' market capitalization is 1.3 B. With a P/B ratio of 3.23, the market values Bicara Therapeutics well above its book equity. Enterprise value stands at 1.01 B. Intrinsic value represents an estimate of underlying worth and can differ from both market price and book value. Valuation methods compare these perspectives to frame context.
Note that
Bicara Therapeutics' intrinsic value and market price are different measures derived from different inputs. For Bicara Therapeutics, key inputs include a P/B ratio of 3.23, and ROE of -26.64%. By contrast, market price reflects the level where buyers and sellers transact.